Today our CEO Al Gianchetti was interviewed by Ali Gorman of BiotechTV and they discussed the exciting progress XyloCor is making with the clinical development of XC001 for patients with refractory angina. In addition, they discussed XyloCor's recent agreement with SmartCella which enables XyloCor to use their Extroducer catheter (use the title from the press release) to deliver XC001 to the heart without the need for a surgical procedure. #Philly #biotech #cardiovascular #genetherapy https://lnkd.in/g_ADHVMV
XyloCor Therapeutics, Inc.
研究服务
Wayne，PA 1,236 位关注者
XyloCor is focused on improving the lives of people with cardiovascular disease through the science of gene therapy.
关于我们
XyloCor Therapeutics is a development-stage, biotechnology company dedicated to developing first-in-class gene therapies for patients with unmet medical need in cardiovascular disease.
- 网站
-
http://xylocor.com
XyloCor Therapeutics, Inc.的外部链接
- 所属行业
- 研究服务
- 规模
- 11-50 人
- 总部
- Wayne，PA
- 类型
- 私人持股
- 创立
- 2013
地点
-
主要
获取路线
1200 Liberty Ridge Drive
Suite 120
US，PA，Wayne，19087
XyloCor Therapeutics, Inc.员工
动态
-
#NEWS: Today, we announced an agreement with Smartwise , a unit of SmartCella Holding AB (“SmartCella”). We have entered into a licensing agreement under which XyloCor has rights to the Extroducer® Infusion Catheter System ®, a first-in-class endovascular device designed to deliver advanced therapies directly into the heart [and hard-to-reach tissues]. XyloCor plans to deploy the Extroducer to support catheter-based endocardial delivery of its lead gene therapy candidate, XC001 (encoberminogene rezmadenovec), in future clinical studies and commercial use. Read more here: https://lnkd.in/edyPaxJy #GeneTherapy #HeartDisease #Innovation #cardiovascular
-
-
#NEWS: Today, we announced positive Phase 2 data for our refractory angina treatment candidate, a novel therapeutic approach that aims to fill a significant unmet medical need for people who have exhausted available treatment options and have a debilitating quality-of-life. Our #clinicaltrial results were also presented today at the Society for Cardiovascular Angiography & Interventions 2024 Scientific Sessions and will be published in the medical journal Circulation: Cardiovascular Interventions. Read more here: https://lnkd.in/edyPaxJy #SCAI2024 #GeneTherapy #HeartDisease #Innovation
-